Q-omics provides the consensus-scored ANKRD31 profile across patient tissues and cancer cell-line models. ANKRD31 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ANKRD31 is differentially expressed in 13, with the highest sampling consensus in THCA. Additionally, ANKRD31 RNA expression shows 18,918 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRP, and THCA as cancer lineages where ANKRD31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKRD31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKRD31 survival associations across molecular data types. ANKRD31 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKRD31 RNA expression–survival associations across cancer types. High ANKRD31 expression shows unfavorable associations in KIRP, THCA and LUAD, but favorable associations in KIRC, PAAD and ESCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for ANKRD31 RNA expression.
This table summarizes ANKRD31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ANKRD31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKRD31 shows lower tumor expression in THCA, HNSC, STAD and UCEC and higher tumor expression in COAD and LUAD. The THCA box plot shows higher ANKRD31 RNA expression in normal versus tumor tissue (log2 FC = −0.220, t-test p < 0.001).
This table shows molecular features associated with ANKRD31 in patient tissues and cancer cell lines. In patient samples, ANKRD31 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKRD31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
